62-year-old survivor found himself in a battle against a formidable adversary: stage 4 adenocarcinoma small cell lung cancer. He received a diagnosis of small cell adenocarcinoma lung cancer in 2020. Initially, they underwent treatment with Carboplatin (AUC 5; 1 day) + Etoposide (100mg/m2; 1-3 days per 3 weeks) for six cycles. However, as the cancer showed resistance to this chemotherapy regimen, the patient was subsequently referred for norm treatment for lung cancer like radiotherapy (56 Gy) in December 2020. Despite enduring various types of systematic treatments, including first-line chemotherapy with cisplatin and etoposide and second-line therapy with topotecan and cisplatin, along with maximum radiotherapy, targeted therapy, and immunotherapy combinations, his condition continued to worsen. The cancer relentlessly progressed, leaving his oncologist with no other options.
62岁的幸存者发现自己在与一个强大的对手作斗争：第四期腺癌小细胞肺癌。他于2020年被诊断出患有腺癌小细胞肺癌。最初，他接受了Carboplatin（AUC 5；1天）+ Etoposide（100mg/m2；每3周1-3天）为期六个疗程的治疗。然而，由于癌症对这种化疗方案显示出抵抗力，患者随后被推荐接受肺癌的规范治疗，比如在2020年12月接受了放疗（56 Gy）。尽管经历了各种系统治疗，包括顺铂和依托泊苷的一线化疗，以及托泊替康和顺铂的二线疗法，再加上最大限度的放疗、靶向治疗和免疫治疗的组合，他的病情继续恶化。癌症不断进展，使他的肿瘤学家别无选择。
He was on Topotecan (4mg/m2/week; 1*8*15 days) for 3 cycles between January – April 2021. Sadly, his body didn’t respond to second line chemotherapy either. In January 2021, he showed signs of progression. He had malignant pleural effusion and mediastinal lymphadenopathy with dyspnea and voice hoarseness.
他在2021年1月至4月之间接受了Topotecan（4mg/m2/周；1815天）为期3个疗程。遗憾的是，他的身体对第二线化疗也没有作出反应。在2021年1月，他显示出疾病进展的迹象。他出现了恶性胸腔积液和纵隔淋巴结肿大，伴有呼吸困难和声音嘶哑。
His oncologist, faced a challenging decision. Out of sheer determination and a desire to explore every possible avenue, he decided to refer him to try ECCT. With little else to offer, his oncology believed it was worth a try given his condition. He embarked on this new journey with a mix of hope and trepidation. To his surprise, after just two months, his mediastinal lymphadenopathy (LAP) began showing signs of improvement.
他的肿瘤学家面临着一个艰难的决定。出于坚定的决心和探索每一种可能途径的愿望，他决定将他推荐尝试经颈动脉途径微波消融细胞治疗（ECCT）。在没有太多其他选择的情况下，他的肿瘤学家认为鉴于他的病情，值得一试。他带着一种希望和忧虑的心情踏上了这段新旅程。令人惊讶的是，仅仅两个月后，他的纵隔淋巴结肿大开始显示出改善的迹象。Encouraged by this newfound ray of hope, he continued the therapy diligently. Four months into the treatment, both his mediastinal LAP and hilar LAP were almost resolved, signaling a significant reduction in tumor burden. The therapy seemed to be working, offering a glimmer of optimism amidst the darkness that had shrouded his life.
受到这一新发现的希望所鼓舞，他继续认真地进行治疗。治疗进行了四个月，他的纵隔淋巴结肿大和肺门淋巴结肿大几乎完全消退，预示着肿瘤负担显著减轻。治疗似乎奏效了，在笼罩他生活的黑暗中带来了一丝乐观的曙光。
As the months went by, his scans revealed continuous improvement. By the end of six months, his mediastinal LAP and hilar LAP had completely resolved. It was an extraordinary outcome, surpassing everyone's expectations. The therapy had not only halted the progression of the cancer but had managed to reverse the damage inflicted upon his body.
随着时间的推移，他的扫描显示出持续改善。六个月后，他的纵隔淋巴结肿大和肺门淋巴结肿大已完全消退。这是一个非凡的结果，超出了所有人的预期。这种治疗不仅停止了癌症的进展，还成功扭转了对他身体造成的损害。Emboldened by his progress, he remained committed to ECCT for a full year. Till to date, he showed no signs of recurrence, providing a much-needed respite from the constant fear and uncertainty that had plagued his life.
在进展的鼓舞下，他坚持了一整年的ECCT治疗。直到今天，他没有显示出任何复发的迹象，为他一直困扰的持续恐惧和不确定性提供了急需的喘息之机。He hope his case inspired hope in many other patients who had exhausted all conventional treatment options. Against all odds, he defied his prognosis and found solace in an experimental therapy that offered him a chance at life. His journey underscored the importance of perseverance, the relentless pursuit of hope, and the potential of cutting-edge technology advancements to change lives.
他希望他的案例能激发许多其他耗尽了所有传统治疗选择的患者的希望。逆境中，他违背了预后，并在一种实验性治疗中找到了生的机会。他的经历强调了坚韧不拔的重要性、对希望的不懈追求以及尖端科技进步改变生活的潜力。
Comments